The Role of Tomotherapy in Hypofractionated/Dose Escalated Conformal Radiation Treatment for High Risk Prostate Cancer

AHS Cancer Control Alberta60 enrolled

Overview

Helical tomotherapy is being used to treat the prostate gland, local rates of spread and regional lymph nodes whilst sparing gross structures. The radiation to the gross disease in the prostate is hypofractionated and dose escalated. Magnetic resonance spectroscopic imaging (MRSI) is incorporated into pre- and post-treatment evaluation.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Prostate Cancer

Interventions

TomotherapyPROCEDURE

Standard 45 Gy in 25 fractions in 5 weeks

Eligibility

Sex: MALEMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * High risk localized prostate cancer Exclusion Criteria: * Low/intermediate risk, metastatic cancer * Patient refusal

Locations (1)

Cross Cancer Institute

Edmonton, Alberta, Canada

Outcomes

Primary Outcomes

Rectal Toxicity

Determine the acute and late rectal toxicity of high-dose short-course hypofractionated radiotherapy in five weeks in the treatment of high rish prostate cancer.

Time frame: 5 weeks

Secondary Outcomes

prostate-specific antigen (PSA) and MRSI disease control

Determine the biochemical control (freedom from PSA failure) rate, overall and disease free survival.

Time frame: 3 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.